Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases. Its primary product is ZEVASKYN, an autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa, a severe skin disorder. The company also has a pipeline of gene therapies for inherited retinal diseases, including ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy. Additionally, Abeona is advancing AAV-based gene therapies through its AIM vector platform. The company operates in the United States and is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ABEO. Trading is conducted in U.S. dollars (USD), which is the official currency of the United States. The NasdaqCM is a U.S.-based stock exchange that lists smaller-cap companies, and Abeona's listing there provides investors with access to its shares in a regulated environment. As a U.S.-domiciled company, all financial reporting and transactions are denominated in USD.

Abeona Therapeutics Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. Biotechnology companies use living organisms or their components to develop drugs and therapies, often focusing on genetic engineering and molecular biology. Abeona specifically specializes in gene and cell therapies, which are advanced treatments that modify a patient's genes or cells to combat diseases. This places it within the biotech subsector of healthcare, a field known for high research and development costs and potential for breakthrough therapies.

Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio, United States. The company was founded in 1974 and was formerly known as PlasmaTech Biopharmaceuticals, Inc. before rebranding to Abeona Therapeutics in June 2015. This rebranding reflected a strategic shift toward gene and cell therapy development. The company's long history, originally in plasma-based products, has evolved into a focus on cutting-edge genetic treatments for severe diseases. Its location in Cleveland places it within a region with a strong healthcare and research infrastructure.

Abeona Therapeutics' lead product is ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, a rare genetic skin condition causing blistering and wounds. The company also has a portfolio of gene therapies for inherited retinal diseases: ABO-503 targets X-linked retinoschisis, ABO-504 is for Stargardt disease, and ABO-505 treats autosomal dominant optic atrophy. Additionally, Abeona is developing AAV-based gene therapies through its AIM vector platform, which aims to improve delivery of therapeutic genes. These programs address serious, life-threatening conditions with significant unmet medical needs.